Sharps Tech Surges 53% on $400M Solana Treasury Funding and SoloGard Deals

Introduction

SHARPS TECHNOLOGY INC (Nasdaq: STSS) is a U.S.-based medical device company that designs and manufactures smart safety syringes. As of August 25, 2025, its shares closed at $11.28, reflecting a 53.37 percent increase on a volume of 2,322,164 shares. The company’s flagship Sharps Provensa™ line, including Ultra-Low Waste™ syringes, aims to eliminate needlestick injuries, prevent needle reuse, and reduce vaccine and medication waste.

Corporate Structure and Workforce

Founded in 2017 and headquartered in Melville, New York, Sharps Technology employs between 51 and 200 staff across research and development, manufacturing, and commercial operations. Its ISO-certified, FDA-cleared facility produces CE-marked devices. The leadership team is led by Chief Executive Officer Robert Hayes and includes a vice president of product and program management.

Smart Syringes by CDC

Recent Developments

On March 6, 2025, CEO Robert Hayes reported the closing of a $20 million financing round, which enabled the elimination of debt and the allocation of capital toward manufacturing expansions in Hungary. In June 2025, the company progressed with a five-year, $50 million SoloGard™ supply agreement with a U.S. medical products partner and began facility upgrades. Additionally, a parallel agreement with a European distributor focused on qualification shipments of SecureGard® syringes to healthcare networks, including Penta Hospitals International. On August 25, 2025, Sharps announced a private placement of over $400 million to establish a Solana digital asset treasury strategy and submitted a Form 8-K detailing those financing activities.

Financial and Strategic Analysis

Sharps Technology registered an employee equity plan (Form S-8) on August 22, 2025, registering 2 million common shares under its 2025 Equity Incentive Plan. A Schedule 13G/A filing on August 14, 2025, indicated that Altium Capital Management entities hold 3.48 percent of the outstanding stock. The August private placement extends the company’s treasury into digital assets and supports liquidity for capital expenditures. Supply agreements for SoloGard and SecureGard are anticipated to generate initial revenues in the second half of 2025, with ongoing U.S. and European collaborations focused on securing recurring purchase orders.

Market Position and Industry Context

The World Health Organization forecasts a global syringe shortage of 1–2 billion units, increasing demand for safety and low-waste designs. Sharps Technology’s products comply with U.S. regulatory and WHO guidelines, positioning the company in a growing medical device market influenced by vaccination campaigns, biologic therapies, diabetes management, and gene treatments. Its manufacturing operations in Hungary—and prospective expansion in South Carolina—aim to enhance cost efficiency and supply-chain resilience.

TL;DR

Sharps Technology closed a $20 million financing round in January 2025 and paid down debt. It anticipates generating revenue from SoloGard™ and SecureGard® contracts in the second half of 2025. On August 25, the company announced a $400 million private placement to fund a Solana digital asset treasury strategy. Sharps Technology has 51–200 employees, operates an ISO-certified facility, and expects further capacity expansion in Hungary and the U.S. to support demand for smart safety syringes.